Literature DB >> 426499

Intravenous use of cephradine and cefazolin against serious infections.

D L Caloza, R W Semar, G E Bernfeld.   

Abstract

The relative efficacy and safety of cephradine and cefazolin were compared in 180 patients with a variety of serious infections caused by susceptible organisms. The patients were randomly assigned to one of two groups of 90 patients each. Most patients received 2 to 4 g per day, administered by intravenous injection in four equally divided doses, for a minimum of 4 days. Based on the clinical and microbiological results, the two cephalosporins were found to be comparable in therapeutic effectiveness. Toxicity was not a problem with either drug.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 426499      PMCID: PMC352609          DOI: 10.1128/AAC.15.1.119

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  Drug therapy: The newer cephalosporins.

Authors:  R C Moellering; M N Swartz
Journal:  N Engl J Med       Date:  1976-01-01       Impact factor: 91.245

2.  Clinical experience with oral cephradine.

Authors:  R R Martin
Journal:  J Ir Med Assoc       Date:  1973-03-24

Review 3.  Cephradine--a summary of preclinical studies and clinical pharmacology.

Authors:  E S Neiss
Journal:  J Ir Med Assoc       Date:  1973-03-24

4.  A study in general practice of cephradine in respiratory tract infections.

Authors:  B Y Marshall
Journal:  Curr Med Res Opin       Date:  1974       Impact factor: 2.580

5.  Use of cephradine in respiratory tract infections.

Authors:  W J Mogabgab
Journal:  J Ir Med Assoc       Date:  1973-03-24

6.  Summary of symposium on cefazolin.

Authors:  D Kaye
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

7.  Utilization of cephradine for suspension in paediatric infections.

Authors:  W G Thurman
Journal:  J Ir Med Assoc       Date:  1973-03-24

8.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

9.  Treatment of urinary tract infections with cephradine.

Authors:  W J Mogabgab
Journal:  Curr Ther Res Clin Exp       Date:  1976-05
  9 in total
  3 in total

Review 1.  Treatment of respiratory tract infections with cephalosporin antibiotics.

Authors:  R Finch
Journal:  Drugs       Date:  1987       Impact factor: 9.546

2.  Cefazolin plasma protein binding and its covariates in neonates.

Authors:  A Smits; A Kulo; R Verbesselt; G Naulaers; J de Hoon; P Vermeersch; K Allegaert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-26       Impact factor: 3.267

3.  Cefradine blocks solar-ultraviolet induced skin inflammation through direct inhibition of T-LAK cell-originated protein kinase.

Authors:  Xiaoming Fan; Qiuhong Duan; Changshu Ke; Guiping Zhang; Juanjuan Xiao; Dan Wu; Xiaoyu Zeng; Jingwen Chen; Jinguang Guo; Jie Zhou; Fei Shi; Feng Zhu
Journal:  Oncotarget       Date:  2016-04-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.